Abstract
Both mild cognitive impairment and fatigue are common among people with HIV/AIDS. This study examined the efficacy of modafinil for HIV+ patients who sought treatment for fatigue in a placebo-controlled double-blind 4-week trial. A battery of standard neuropsychological tests was administered at study entry and Week 4, and change in performance was compared for 59 patients receiving modafinil versus 44 patients receiving placebo. A significant effect on fatigue was observed. In addition, cognitive performance, as measured by a global change score, improved more in the modafinil than in the placebo group although the effect was not specific to any cognitive domain.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Aged
-
Analysis of Variance
-
Benzhydryl Compounds / therapeutic use*
-
CD4 Antigens / metabolism
-
Central Nervous System Stimulants / therapeutic use*
-
Cognition Disorders / drug therapy*
-
Cognition Disorders / etiology*
-
Double-Blind Method
-
Fatigue / complications
-
Fatigue / drug therapy
-
Fatigue / etiology*
-
Female
-
HIV Infections / blood
-
HIV Infections / complications*
-
HIV Infections / drug therapy
-
Humans
-
Language
-
Male
-
Middle Aged
-
Modafinil
-
Psychiatric Status Rating Scales
-
Psychometrics
-
RNA Viruses
-
Severity of Illness Index
-
Viral Load / methods
-
Young Adult
Substances
-
Benzhydryl Compounds
-
CD4 Antigens
-
Central Nervous System Stimulants
-
Modafinil